The objective of the proposed research is to elucidate the molecular basis for species differences in the metabolism of two model polychlorinated biphenyls (PCBs) by the major phenobarbital-inducible forms of cytochrome P450 from dogs, rabbits, and rats. PCBs have been widely used in industry due to their resistance to thermal, chemical and biological degradation. This high stability has led to the persistence of PCBs in the environment, and the toxicity associated with many PCBs poses a serious human health hazard. One of the key factors that determines the stability in the environment and in animal and human tissues of PCBs is their metabolism. In general, highly chlorinated PCBs lacking two adjacent unsubstituted sites on one of the phenyl rings, are metabolized slowly by micro- organisms and mammals. One such compound which is highly persistent in the environment and in human tissues and breast milk is 2,2',4,4',5,5'- hexachlorobiphenyl (245-HCB), a known tumor promoter in rats. Of all species tested to date, only the dog appears to be able to metabolize and eliminate 245-HCB efficiently. This metabolism is attributable to a cytochrome P450 that is a member of the P450IIB (phenobarbital- inducible) subfamily in dog liver. The dog P450IIB is also active in the metabolism of 2,2',3,3;,6,6'-hexachlorobiphenyl (236-HCB), which has adjacent unsubstituted sites on both phenyl rings. In contrast, the structurally related cytochromes P450IIB in the rabbit and rat metabolize 245-HCB poorly, although rat P450IIB1 can metabolize 236-HCB. Presumably, electronic and steric properties of the enzymes and of the PCBs dictate which cytochromes P450IIB can metabolize which hexachlorobiphenyls. The hypothesis to be tested is that amino acid residues required for the metabolism of 245-HCB and 236-HCB by cytochromes P450IIB can be identified. The basic approach will be to express in heterologous systems cDNAs encoding native, hybrid, and mutant forms of the enzymes. These will be assayed for their ability to metabolize not only the two hexachlorobiphenyls but also the two model substrates androstenedione and progesterone. The steroids will serve as positive control of the overall functional integrity of any hybrid or mutant enzymes since the native cytochromes P450 from all three species hydroxylate these compounds. These studies should provide the rational basis for the design of superior catalysts of PCB detoxification.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
2R01ES004995-04
Application #
3253198
Study Section
Toxicology Subcommittee 2 (TOX)
Project Start
1989-02-01
Project End
1997-03-31
Budget Start
1992-04-01
Budget End
1993-03-31
Support Year
4
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
Schools of Pharmacy
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Szklarz, G D; Halpert, J R (1998) Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. Drug Metab Dispos 26:1179-84
Szklarz, G D; Halpert, J R (1997) Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. Life Sci 61:2507-20
Harlow, G R; He, Y A; Halpert, J R (1997) Functional interaction between amino-acid residues 242 and 290 in cytochromes P-450 2B1 and 2B11. Biochim Biophys Acta 1338:259-66
Harlow, G R; Halpert, J R (1996) Mutagenesis study of Asp-290 in cytochrome P450 2B11 using a fusion protein with rat NADPH-cytochrome P450 reductase. Arch Biochem Biophys 326:85-92
Fang, X; Halpert, J R (1996) Dithionite-supported hydroxylation of palmitic acid by cytochrome P450BM-3. Drug Metab Dispos 24:1282-5
Liu, J; He, Y A; Halpert, J R (1996) Role of residue 480 in substrate specificity of cytochrome P450 2B5 and 2B11. Arch Biochem Biophys 327:167-73
Born, S L; John, G H; Harlow, G R et al. (1995) Characterization of the progesterone 21-hydroxylase activity of canine cytochrome P450 PBD-2/P450 2B11 through reconstitution, heterologous expression, and site-directed mutagenesis. Drug Metab Dispos 23:702-7
Klekotka, P A; Halpert, J R (1995) Benzyloxyresorufin as a specific substrate for the major phenobarbital-inducible dog liver cytochrome P450 (P4502B11). Drug Metab Dispos 23:1434-5
John, G H; Hasler, J A; He, Y A et al. (1994) Escherichia coli expression and characterization of cytochromes P450 2B11, 2B1, and 2B5. Arch Biochem Biophys 314:367-75
Hasler, J A; Harlow, G R; Szklarz, G D et al. (1994) Site-directed mutagenesis of putative substrate recognition sites in cytochrome P450 2B11: importance of amino acid residues 114, 290, and 363 for substrate specificity. Mol Pharmacol 46:338-45

Showing the most recent 10 out of 16 publications